Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast

The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes already on the market for type 2 diabetes (e.g., SGLT-2 inhibitors), but a few early-phase agents (e.g., VX-880) offer a novel mechanism of action. The emphasis has shifted on the types of therapies in development for T1D; interest in pancreatic beta-cell replacement therapies and CD3 antigen inhibitors is significant. The availability of biosimilar insulins is also likely to have a sizable effect on the T1D therapy market throughout the G7, resulting in an intricate interplay of physician and payer attitudes toward this treatment option.

QUESTIONS ANSWERED

  • What are the drivers and constraints in the T1D market, and how will the market evolve over the forecast period?
  • How are biosimilar insulins being adopted in the markets under study?
  • What impact will the increasing use of insulin pumps have on market dynamics?
  • How will endocrinologists differentiate between the emerging therapies, and which agents will enjoy the most clinical and commercial success in an increasingly stringent regulatory and cost-sensitive environment?
  • How will ultra-rapid insulins, such as Novo Nordisk’s Fiasp and Eli Lilly’s Lyumjev, be incorporated into treatment in the major markets?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Type 1 Diabetes - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • [[FOR OLDER REPORTS ONLY]]
        • A note about this report
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
    • Key Findings
      • Type 1 Diabetes - Key Findings - December 2019
        • March 2022
        • February 2022
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Type 1 Diabetes: 2018
        • Market Share of Drug Classes for Type 1 Diabetes: 2028
        • Type 1 Diabetes SWOT Analysis
      • COVID-19: Areas of Potential Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Type 1 Diabetes?
          • What Factors Are Constraining the Market for Type 1 Diabetes?
          • T1D Sales and Patient Share by Drug Class: Major Markets 2018-2028
          • T1D Patient Share of Insulins Split by Brand / Biosimilar: Major Markets 2018-2028
        • Drug-Class Specific Trends
          • Long-acting Insulins
          • T1D Sales and Patient Share for Long-acting Insulins: Adult Population, Major Markets 2018-2028
          • Rapid-acting Insulins
          • T1D Sales and Patient Share for Rapid-acting Insulin: Adult Population, Major Markets 2018-2028
          • T1D Sales and Patient Share for SGLT Inhibitors: Adult Population, Major Markets 2018-2028
          • T1D Sales and Patient Share for Teplizumab: United States, Adult and Child Populations, 2018-2028
      • Forecast
        • Market Forecast Assumptions - Type 1 Diabetes 2018-2028 - December 2019
        • Market Forecast Dashboard - Type 1 Diabetes 2018-2028 - December 2019
      • Etiology and Pathophysiology
        • Disease Overview
          • Etiology
            • Risk Factors for Type 1 Diabetes
          • Pathophysiology
            • Type 1 Diabetes: How the Disease Might Arise
          • Natural History
            • Key Pathways and Drug Targets
              • Summary of Type 1 Diabetes Drug Targets
          • Epidemiology Overview
            • Key Findings
              • Epidemiology Populations
                • Disease Definition
                • Methods
                • Sources Used for Diagnosed Prevalence Estimates of Type 1 Diabetes
                • Diagnosed Prevalent Cases of Type 1 Diabetes : 2021-2031 (thousands)
                • Drug-Treated Prevalent Cases of Type 1 Diabetes: 2018-2028
            • Current Treatment
              • Key Findings
                • Treatment Goals
                  • Key Endpoints Used in Clinical Trials for Type 1 Diabetes
                • Key Current Therapies
                  • Overview
                  • Mechanism of Action of Key Current Drugs Used for Type 1 Diabetes
                  • Current Treatments Used for Type 1 Diabetes
                  • Advantages and Disadvantages of Glargine U100
                  • Ongoing Clinical Development of Glargine U100
                  • Expert Insight: Glargine U100
                  • Advantages and Disadvantages of Detemir
                  • Ongoing Clinical Development of Detemir
                  • Expert Insight: Detemir
                  • Advantages and Disadvantages of Degludec
                  • Ongoing Clinical Development of Degludec
                  • Expert Insight: Degludec
                  • Advantages and Disadvantages of Glargine U300
                  • Ongoing Clinical Development of Glargine U300
                  • Expert Insight: Glargine U300
                  • Advantages and Disadvantages of Aspart
                  • Ongoing Clinical Development of Aspart
                  • Expert Insight: Aspart
                  • Advantages and Disadvantages of Glulisine
                  • Ongoing Clinical Development of Glulisine
                  • Expert Insight: Glulisine
                  • Advantages and Disadvantages of Lispro
                  • Ongoing Clinical Development of Lispro
                  • Expert Insight: Lispro
                  • Advantages and Disadvantages of Technosphere
                  • Ongoing Clinical Development of Technosphere
                  • Expert Insight: Technosphere
                  • Advantages and disadvantages of ultra-rapid aspart
                  • Ongoing clinical development of ultra-rapid aspart
                  • Expert insight: ultra-rapid aspart
                  • Advantages and disadvantages of ultra-rapid lispro
                  • Ongoing clinical development of ultra-rapid lispro
                  • Advantages and disadvantages of regular insulin
                  • Advantages and disadvantages of NPH insulin
                  • Advantages and disadvantages of premixed insulins
                  • Expert insight: premixed insulin
                  • Advantages and disadvantages of dapagliflozin
                  • Ongoing clinical development of dapagliflozin
                  • Expert insight: dapagliflozin
                  • Advantages and disadvantages of ipragliflozin
                  • Ongoing clinical development of ipragliflozin
                  • Expert insight: ipragliflozin
                  • Advantages and disadvantages of pramlintide
                  • Ongoing clinical development of pramlintide
                  • Expert insight: pramlintide
                • Medical practice
                  • Overview
                  • Country-specific treatment guidelines for type 1 diabetes
                  • Factors influencing drug selection in type 1 diabetes
                  • Generalized treatment decision tree for type 1 diabetes: major markets
              • Unmet Need Overview
                • Current and Future Attainment of Unmet Needs in Type 1 Diabetes
                • Top Unmet Needs in Type 1 Diabetes: Current and Future Attainment
              • Emerging Therapies
                • Key Findings
                  • Key emerging therapies
                    • Key therapies in development for type 1 diabetes
                    • Estimated launch dates of key emerging therapies for the treatment of type 1 diabetes
                    • Sotagliflozin profile
                    • Analysis of the clinical development program for sotagliflozin
                    • Expert insight: sotagliflozin
                    • Expectations for launch and sales opportunity of sotagliflozin in type 1 diabetes
                    • Teplizumab profile
                    • Analysis of the clinical development program for teplizumab
                    • Expert insight: teplizumab
                    • Expectations for launch and sales opportunity of teplizumab in type 1 diabetes
                    • Key results from select clinical trials investigating ladarixin for the treatment of type 1 diabetes
                    • Key ongoing clinical trials of ladarixin for the treatment of type 1 diabetes
                    • Analysis of the clinical development program for ladarixin
                    • Expectations for launch and sales opportunity of ladarixin in type 1 diabetes
                    • Key results from select clinical trials investigating Diamyd for the treatment of type 1 diabetes
                    • Key ongoing clinical trials of Diamyd for the treatment of type 1 diabetes
                    • Analysis of the clinical development program for Diamyd
                    • Expectations for launch and sales opportunity of Diamyd in type 1 diabetes
                  • Early-phase pipeline analysis
                    • Select compounds in phase II development for type 1 diabetes
                • Access & Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in Type 1 Diabetes: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in Type 1 Diabetes: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in Type 1 Diabetes: Japan
                    • General Reimbursement Environment: Japan
                  • Looking for More?
                • Appendix
                  • Key Abbreviations Related to Type 1 Diabetes
                  • Brands, Marketers, and Generic Availability of Key Therapies for Type 1 Diabetes: by Market
                  • Type 1 Diabetes Bibliography

              launch Related Market Assessment Reports